La cadena de opciones muestra datos clave de las opciones de acciones de Inventiva a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Inventiva..

Inventiva (NASDAQ:IVA) Bolsa, Cadena de Opciones

Inventiva

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Inventiva S.A. - American Depository Shares

Inventiva SA

Intevac Inc

INVESCO ARTIFICIAL INTEL ETF

Alpha Architect International Quantitative Value ETF

Telsey Advisory Group analyst Dana Telsey maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Outperform and raises the price target from $183 to $190.

News

Price Target

Analyst Ratings

DECK

Telsey Advisory Group Maintains Outperform on Deckers Outdoor, Raises Price Target to $190

Trading Ideas

ASML

MSCI

Third Point 13F Shows Exited Position In International Flavors & Fragrances, Previously Holding 1,300,000 Shares; Advance Auto Parts, Previously Holding 1,500,100 Shares; ASML Holding, Previously Holding 80,000 Shares; MSCI, Previously Holding 150,000 Shares; Micron Technology Inc, Previously Holding 275,000 Shares

Earnings

Retractable Technologies Q3 Sales $10.3M, Flat YoY

Federal Reserve Chair Jerome Powell's unexpectedly hawkish remarks on Thursday sent markets into a tailspin. Major U.S. equity indices closed in the red, and the dollar soared for <a href="https://www.benzinga.com/topic/interest-rates">a fifth consecutive session</a>.
In a speech to Dallas business leaders, Powell highlighted the remarkable strength of the U.S. economy, indicating that there's no need for the Fed to &#8220;be in a hurry to lower rates.&#8221;
He reiterated the central bank's commitment to reaching its 2% inflation target, stressing the need for careful decision-making as inflation remains above desired levels.
He highlighted productivity gains, which he said have &#8220;grown faster over the past five years than at any point in the two decades preceding the pandemic,&#8221; positioning the U.S. economy as &#8220;the best-performing among major economies.&#8221;
Addressing the October <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41971830/producer-inflation-rises-more-than-expected-in-october-should-traders-rethink-interest-rate-cut-path">producer price index (PPI) uptick</a>, Powell labeled it &#8220;more than an upward bump&#8221; but maintained confidence in the trajectory toward the 2% inflation goal.
<h3 class="wp-block-heading">Markets Reassess Interest Rate Path: Traders Are Less Confident On A December Cut</h3>
Powell&#8217;s comments impacted the interest-rate market, with fed futures now reflecting a reduced likelihood of a 25-basis-point cut in December. 
The CME FedWatch tool shows the odds of such a move dropped to 58%, sharply down from around 80% earlier in the day.
The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), closed down 0.6%, fully erasing gains from last week&#8217;s rate cut. Energy was the only sector in positive territory, rising 0.4%, while industrials and health care led declines, each down 0.7%.
Top performers in the S&amp;P 500 included Tapestry Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>), Wynn Resorts Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>), and First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), which rose 12.8%, 8.7%, and 7.2%, respectively. Among the laggards were Leidos Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) and Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), down 13.6% and 11.4%, respectively.
Tech stocks, as tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), declined 0.7%, marking a fourth consecutive loss. Blue chips followed by the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) slipped 0.5%, while small caps in the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) underperformed, falling 1.3%.
The dollar continued to attract liquidity, with the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) logging a fifth consecutive gain, reaching levels last seen in late October 2023.
Treasury yields also rose, with the 10-year yield closing at 4.46%. Gold, tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), marked its fifth straight loss.
In crypto markets, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was 1.7% lower in the past 24 hours to $88,013 at 5:21 p.m. ET, on track for its worst day in November.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41984852/trumps-red-wave-pushes-emerging-market-stocks-to-2-month-lows-volatility-expected-to-remain-elevated">Trump&#8217;s Red Wave Pushes Emerging Market Stocks To 2-Month Lows: Volatility &#8216;Expected To Remain Elevated&#8217; </a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Bonds

Broad U.S. Equity ETFs

Specialty ETFs

Commodities

Currency ETFs

Treasuries

Economics

Federal Reserve

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

FSLR

LDOS

SMCI

PowerShares DB US Dollar Index Bullish Fund

WYNN

Powell's Hawkish Remarks Shake Markets: Stocks Fall, Dollar Rockets, Bitcoin Dips

WIIM

TMC Metals shares are trading higher. The company reported Q3 financial results.

Telsey Advisory Group analyst Cristina Fernandez upgrades Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) from Market Perform to Outperform and raises the price target from $11 to $12.

Upgrades

ARHS

Telsey Advisory Group Upgrades Arhaus to Outperform, Raises Price Target to $12

Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.57) by 10.53 percent.

Earnings Beats

BCLI

Brainstorm Cell Q3 2024 GAAP EPS $(0.51) Beats $(0.57) Estimate

TIVC

Tivic Health Systems shares are trading lower after the company reported a year-over-year decline in Q3 sales results.

D. Boral Capital analyst Jason Kolbert maintains Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) with a Buy and maintains $12 price target.

QNCX

D. Boral Capital Maintains Buy on Quince Therapeutics, Maintains $12 Price Target

OCTO

Eightco Holdings Q3 Sales $7.7M Down From $23.3M YoY

Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) reported quarterly losses of $(8.81) per share which missed the analyst consensus estimate of $(6.12) by 43.95 percent. The company reported quarterly sales of $57.000 million which beat the analyst consensus estimate of $58.000 thousand by 98.18K percent.

Earnings Misses

TRAW

Traws Pharma Q3 2024 GAAP EPS $(8.81) Misses $(6.12) Estimate, Sales $57.000M Beat $58.000K Estimate

GOOGL

UBER

Third Point 13F Shows Exited Position In Alphabet, Previously Holding 1,980,000 Shares; American Intl Group, Previously Holding 3,450,000 Shares; Verizon Communications, Previously Holding 4,675,000 Shares; Uber Technologies Inc, Previously Holding 2,100,000 Shares; KB Home, Previously Holding 2,100,000 Shares

Billionaire investor Warren Buffett cut several of Berkshire Hathaway Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) <a href="https://www.benzinga.com/markets/equities/24/08/40232279/is-warren-buffett-bearish-or-waiting-to-pounce-berkshire-now-owns-more-t-bills-than-federal-rese">largest holdings this year</a>. 
The Omaha, Nebraska-based holding company&#8217;s latest 13F filing shows that the sell-off trend continues.
What Happened: Berkshire&#8217;s latest 13F filing, filed on Thursday, reflects the company&#8217;s largest holdings as of September 30.
Buffett reduced his stake in Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from 400 million to 300 million shares. Thus, Berkshire has now cut its position in the Cupertino, California-based tech giant by over two-thirds since 2023&#8217;s third quarter.
The Omaha &#8220;oracle&#8221; also continued to cut his stake in Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), trimming back another 23% of Berkshire&#8217;s position.
Berkshire cut nearly all of its position in Ulta Beauty Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>). Buffett <a href="https://www.benzinga.com/markets/equities/24/08/40385824/warren-buffett-still-holds-400m-apple-shares-reveals-new-investments-in-ulta-beauty-and-heico-el">revealed a position in the cosmetic store chain</a> in August; the company&#8217;s stock has performed roughly even since then. Buffett&#8217;s Ulta holding period was unusually short for the famed value investor.
Meanwhile, Buffett added a couple of fresh faces to Berkshire&#8217;s portfolio.
Buffett bought 1,277,256 shares of Ann Arbor, Michigan-based pizza chain Domino&#8217;s Pizza Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>). He also made a foray into pool equipment, buying 404,057 shares of Pool Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>).
Price Action: Investors quickly reacted to Berkshire&#8217;s 13F filing after hours:
<ul>
<li>Dominoes Pizza shares traded up nearly 7%.</li>
<li>Pool Corp shares traded up nearly 6%.</li>
<li>Ulta Beauty shares fell over 4%.</li>
<li>Apple and Bank of America shed insignificant portions of their market value.</li>
</ul>
Why it Matters: During Berkshire&#8217;s annual shareholder meeting in May, Buffett hinted that his sell-offs were a result of tax implications. 
This <a href="https://www.benzinga.com/markets/equities/24/08/40385824/warren-buffett-still-holds-400m-apple-shares-reveals-new-investments-in-ulta-beauty-and-heico-el">has not stopped</a> investors&#8217; conjecture that Buffett is perhaps bearish <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">on the market at large</a>.
Alternatively, Buffett could be simply trimming positions that take up an outsized portion of Berkshire&#8217;s portfolio to reduce exposure.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a></li>
</ul>
Image via Flickr

AAPL

POOL

ULTA

Warren Buffett's Berkshire Hathaway Slashes Apple, BofA Holdings, Adds Domino's Pizza In Q3

LGCY

Legacy Education shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.55) by 12.73 percent.

BNTC

Benitec Biopharma Q1 2025 GAAP EPS $(0.48) Beats $(0.55) Estimate

MLSS

Milestone Scientific shares are trading higher after the company reported better-than-expected Q3 financials.

Hedge Funds

General

MRCY

Starboard Value's Q3 2024 13F Filing Reveals Complete Exits From Mercury Systems With 2.29M Shares, AECOM With 625K Shares

BENF

Beneficient shares are trading higher after the company reported a year-over-year increase in Q2 revenue results.

OPTX

Syntec Optics Holdings Q3 EPS $0.00 Down From $0.01 YoY, Sales $7.86M Up From $6.6M YoY

Billionaire investor Chase Coleman's hedge fund, Tiger Global Management, filed its latest <a href="https://www.sec.gov/Archives/edgar/data/1167483/000091957424006690/xslForm13F_X02/infotable.xml">Form 13F</a> on Thursday and disclosed its trading activity from the prior quarter. Here's a look at Tiger Global's <a href="https://www.benzinga.com/opinion/24/08/40422936/steal-these-two-stock-ideas-from-the-best-investors-in-the-world">portfolio changes.&nbsp;</a>
The Details: Tiger Global has $23.439 billion in assets under management and made no changes to its top five holdings:&nbsp;
<ul>
<li>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) </li>
<li>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) </li>
<li>Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) </li>
<li>Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) </li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) </li>
</ul>
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a>
New Positions: Tiger Global opened three new positions including a $801.3 million stake in Flutter Entertainment Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>), the parent company of FanDuel. The fund also opened a $201.4 million position in Sherwin-Williams Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) and a $48.9 million position in South Korean e-commerce platform Coupang, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>). 
Notable Trades: Tiger Global added 564,090 shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) to its portfolio, bringing its total number of shares owned to 3,634,980. The fund also increased its stake in Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) by 195,714 shares, bringing its current holdings to 5,839,256 shares valued at $897.5 million. 
Closed Positions: The hedge fund closed out its positions in Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) and DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Image created using artificial intelligence via MidJourney.

Movers

ALAB

CPNG

DXCM

FLUT

MSFT

TTWO

Tiger Global Hedge Fund Buys Flutter Entertainment Stock, Sells DexCom

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aytu BioScience (AYTU – Research Report), Inventiva ...

Analysts Are Bullish on These Healthcare Stocks: Aytu BioScience (AYTU), Inventiva (IVA)

Inventiva secures financing of up to €348M to advance the Nativ3 phase 3 MASH study

Inventiva (IVA) has released an update. Inventiva S.A. plans a significant capital raise through the issuance of new ordinary shares and pre-funded...

Inventiva S.A. Plans Significant Capital Raise

Ed Arce, an analyst from H.C. Wainwright, maintained the Buy rating on Inventiva (IVA – Research Report). The associated price target was lowered t...

Inventiva Secures €348 Million Financing, Reinforcing Buy Rating Amid Strategic Advancements

Inventiva (IVA) has released an update. Inventiva S.A.'s interim financial report for the first half of 2024 highlights key events and provides an ...

Inventiva's 2024 Interim Financial Highlights and Prospects

Inventiva (IVA) announced the recommendation from the fifth scheduled meeting of the Data Monitoring Committee, or DMC, to continue the NATiV3 Phas...

Inventiva announces DMC recommendation to continue NATiV3 trial as is

Inventiva (IVA) has released an update. Inventiva has announced a positive recommendation from the Data Monitoring Committee for its NATiV3 Phase 3...

Inventiva Gains Positive Nod for Lanifibranor Trial

Inventiva (IVA) has received a new Hold rating, initiated by UBS analyst, Eliana Merle. Eliana Merle's rating is based on the promising potential o...

Cautious Optimism for Inventiva's Lanifibranor Amidst Execution Challenges and Dilution Risks

UBS initiated coverage of Inventiva (IVA) with a Neutral rating and $3 price target The firm thinks the company's pan-PPAR agonist lanifibranor, cu...

Inventiva initiated with a Neutral at UBS

Inventiva (IVA) has released an update. Inventiva S.A. has scheduled its Joint Ordinary & Extraordinary General Meeting of Shareholders for Decembe...

Inventiva S.A. Plans Key Shareholder Meeting in December

AYTU

DRRX

Press Releases

Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position

Inventiva announces a €20.1 million issuance of royalty certificates

Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

Inventiva Reports Preliminary 2024 First-Half Financial Information¹

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report

Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

Comments

Inventiva

Inventiva (IVA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL